SFSIG
NKTR icon

San Francisco Sentry Investment Group’s Nektar Therapeutics NKTR Stock Holding History

San Francisco Sentry Investment Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-2
Closed – – 932
2019
Q3 		$0 Buy
+2
New +$733 ﹤0.01% 927
2018
Q4 		– Sell
-2
Closed -$2K – 1042
2018
Q3 		$2K Buy
+2
New +$1.71K ﹤0.01% 792
2014
Q2 		– Sell
-164
Closed -$30K – 649
2014
Q1 		$30K Hold
164
– – 0.01% 413
2013
Q4 		$28K Hold
164
– – 0.01% 390
2013
Q3 		$26K Hold
164
– – 0.01% 386
2013
Q2 		$28K Buy
+164
New +$25.2K 0.01% 377

Other funds holding NKTR

Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $8.67B AUM 48.76% 1-Year Est. Return

San Francisco Sentry Investment Group's NKTR Position: Q4 2019 in Review

San Francisco Sentry Investment Group sold out of Nektar Therapeutics (NKTR) in Q4 2019, closing a stake of 2 shares.

San Francisco Sentry Investment Group first reported a position in NKTR in Q2 2013 and held it in 6 quarters. The position peaked at $30K in Q1 2014. 280 funds tracked by Wall St. Rank hold NKTR as of Q4 2019.

  • San Francisco Sentry Investment Group reported no remaining Nektar Therapeutics position as of Q4 2019 after selling out during the quarter.
  • San Francisco Sentry Investment Group sold 2 Nektar Therapeutics shares in Q4 2019.
  • San Francisco Sentry Investment Group first reported a position in Nektar Therapeutics in Q2 2013 and held it in 6 quarters.
  • San Francisco Sentry Investment Group's Nektar Therapeutics position peaked at $30K in Q1 2014.
  • 280 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q4 2019.

Based on San Francisco Sentry Investment Group's 13F filing for Q4 2019, filed 30 Jan 2020.